

DAFTAR PUSTAKA

1. Traish AM. Benefits and Health Implications of Testosterone Therapy in Men With Testosterone Deficiency. *Sex Med Rev.* 2018;6(1):86–105.
2. Li Y, Zhang M, Liu X, Cui W, Rampersad S, Li F, et al. Correlates and prevalence of hypogonadism in patients with early- and late-onset type 2 diabetes. *Andrology.* 2017;5(4):739–43.
3. Ross A, Bhasin S. Hypogonadism: Its Prevalence and Diagnosis. *Urol Clin North Am.* 2016;43(2):163–76.
4. Baillargeon J, Urban RJ, Zhang W, Zaiden MF, Javed Z, Sheffield-Moore M, et al. Testosterone replacement therapy and hospitalization rates in men with COPD. *Chron Respir Dis.* 2018;16.
5. Desroches B, Kohn TP, Welliver C, Pastuszak AW. Testosterone therapy in the new era of food and drug administration oversight. *Transl Androl Urol.* 2016;5(2):207–12.
6. Haring R, Ittermann T, Völzke H, Krebs A, Zygmunt M, Felix SB, et al. Prevalence, incidence and risk factors of testosterone deficiency in a population-based cohort of men: Results from the study of health in Pomerania. *Aging Male.* 2010;13(4):247–57.
7. Anaissie J, DeLay KJ, Wang W, Hatzichristodoulou G, Hellstrom WJ. Testosterone deficiency in adults and corresponding treatment patterns across the globe. *Transl Androl Urol.* 2017;6(2):183–91.
8. Yassin A, Haider A, Haider KS, Caliber M, Doros G, Saad F, et al. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: Eight-year data from a registry study. *Diabetes Care.* 2019;42(6):1104–11.
9. O'Reilly MW, Glisic M, Kumarendran B, Subramanian A, Manolopoulos KN, Tahrani AA, et al. Serum testosterone, sex hormone-binding globulin and sex-specific risk of incident type 2 diabetes in a retrospective primary care cohort. *Clin Endocrinol (Oxf).* 2019;90(1):145–54.
10. Weiss R, Santoro N, Giannini C, Galderisi A, Umamo GR, Caprio S. Prediabetes in youths: mechanisms and biomarkers. *Lancet Child Adolesc*

- Heal. 2017;1(3):240–8.
11. DHHS. National diabetes statistics report, 2020. *Natl Diabetes Stat Rep.* 2020;2.
 12. Hostalek U. Global epidemiology of prediabetes - present and future perspectives. *Clin Diabetes Endocrinol.* 2019;5(1):1–5.
 13. Fernandes NLT, Nackeeran S, Rakitina E, Fernandes NLG, Arora H, Kargi AY, et al. Association of leptin with total and free testosterone: results from the National Health and Nutrition Examination Surveys. *Androg Clin Res Ther.* 2020;1(1):94–100.
 14. Rehman K, Akash MSH. Mechanism of generation of oxidative stress and pathophysiology of type 2 diabetes mellitus: How are they interlinked?. *J Cell Biochem.* 2017;118(11):3577–85.
 15. Agbecha A, Usoro CAO. Serum testosterone and insulin resistance in type 2 male diabetics attending university of calabar teaching hospital, Nigeria. *JMS - J Med Soc.* 2017;31(3):178–84.
 16. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. type 2 diabetes and insulin resistance. *J Androl.* 2009;30(1):23–32.
 17. Boeri L, Capogrosso P, Ventimiglia E, Pederzoli F, Frego N, Cazzaniga W, et al. Undiagnosed prediabetes is highly prevalent in primary infertile men – results from a cross-sectional study. *BJU Int.* 2019;123(6):1070–7.
 18. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in Men with type 2 diabetes. *Eur J Endocrinol.* 2013;169(6):725–33.
 19. Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. *Am J Epidemiol.* 1996;143(9):889–97.
 20. ADA. ADA standards of diabetes care 2021. Vol. 44, *The journal of clinical and applied research and education.* 2021. p. S21–226.
 21. Morales alvaro, Bebb RA, Manjoo P, Assimakopoulos P, Axler J, Collier C, et al. Diagnosis and management of testosterone deficiency syndrome in

- men : clinical practice guideline. *CMAJ*. 2015;187(18):1369–77.
22. PERKENI. Pengelolaan dan pengobatan diabetes melitus tipe 2 dewasa. Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 di Indonesia. 2019;1:132.
 23. Gianatti EJ, Grossmann M. Testosterone deficiency in men with Type 2 diabetes: pathophysiology and treatment. *Diabet Med*. 2020;37(2):174–86.
 24. Liu CC, Huang SP, Cheng KH, Hsieh TJ, Huang CN, Wang CJ, et al. Lower SHBG level is associated with higher leptin and lower adiponectin levels as well as metabolic syndrome, independent of testosterone. *Sci Rep*. 2017;7(1):1–8.
 25. Ibrahim I, Oenzil F, Amir A. Hubungan obesitas dengan hormon testosteron pada mahasiswa STIKes Indonesia Padang. *J Kesehat Andalas*. 2015;4(3):772–6.
 26. Al Hayek A, Ajlouni K, Khader Y, Jafal S, Khawaja N, Robert A. Prevalence of low testosterone levels in men with type 2 diabetes mellitus: a cross-sectional study. *J Fam Community Med*. 2013;20(3):179.
 27. Bansal N. Prediabetes diagnosis and treatment: A review. *World J Diabetes*. 2015;6(2):296.
 28. Aamir AH, Ul-Haq Z, Mahar SA, Qureshi FM, Ahmad I, Jawa A, et al. Diabetes prevalence survey of Pakistan (DPS-PAK): Prevalence of type 2 diabetes mellitus and prediabetes using HbA1c: A population-based survey from Pakistan. *BMJ Open*. 2019;9(2):1–9.
 29. Manaf A. Insulin : Mekanisme sekresi dan aspek metabolisme. dalam: Setiati S, Alwi I, Sudoyo A, Simadibrata M, Setyohadi B, Syam A, ed. *Buku Ajar Ilmu Penyakit Dalam Jilid III Edisi VI*. Jakarta: Interna Publishing; 2014. 2350–4.
 30. Wysham C, Shubrook J. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications. *Postgrad Med*. 2020;132(8):676–86.
 31. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: A high-risk state for diabetes development. *Lancet*. 2012;379(9833):2279–90.
 32. Goel P, Popa AR. The relation between metabolic syndrome and testosterone

- level. *Rom J Diabetes Nutr Metab Dis.* 2018;25(1):109–14.
33. Fernandez CJ, Chacko EC, Pappachan JM. Male obesity-related secondary hypogonadism – pathophysiology, clinical implications and Management. *Eur Endocrinol.* 2019;15(2):83–90.
 34. Osuna C JA, Gómez-Pérez R, Arata-Bellabarba G, Villaroel V. Relationship between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and insulin resistance in obese men. *Arch Androl.* 2006;52(5):355–61.
 35. Kahn BE, Brannigan RE. Obesity and male infertility. *Curr Opin Urol.* 2017;27(5):441–5.
 36. Khripun I, Vorobyev S, Belousov I, Kogan M, Zitzmann M. Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial. *Aging Male.* 2019;22(4):241–9.
 37. Xu W, Morford J, Mauvais-Jarvis F. Emerging role of testosterone in pancreatic β cell function and insulin secretion. *J Endocrinol.* 2019;240(3):R97–105.
 38. Svartberg J, Von Mühlen D, Sundsfjord J, Jorde R. Waist circumference and testosterone levels in community dwelling men. The Tromsø study. *Eur J Epidemiol.* 2004;19(7):657–63.
 39. Ghadge AA, Khaire AA. Leptin as a predictive marker for metabolic syndrome. *Cytokine.* 2019;121:154735.
 40. Amjad S, Baig M, Zahid N, Tariq S, Rehman R. Association between leptin, obesity, hormonal interplay and male infertility. *Andrologia.* 2019;51(1):1–7.
 41. Moini J. *Epidemiology of diabetes.* 1st ed. Elsevier Inc.; 2019. 95–118.
 42. Rao PM, Kelly DM, Jones TH. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. *Nat Rev Endocrinol.* 2013;9(8):479–93.
 43. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. *Eur J Endocrinol.*

- 2007;156(5):595–602.
44. Lysiak JJ. The role of tumor necrosis factor-alpha and interleukin-1 in the mammalian testis and their involvement in testicular torsion and autoimmune orchitis. *Reprod Biol Endocrinol*. 2004;2:1–10.
 45. Mohamad NV, Wong SK, Wan Hasan WN, Jolly JJ, Nur-Farhana MF, Ima-Nirwana S, et al. The relationship between circulating testosterone and inflammatory cytokines in men. *Aging Male*. 2019;22(2):129–40.
 46. Ohlander SJ, Lindgren MC, Lipshultz LI. Testosterone and male infertility. *Urol Clin North Am*. 2016;43(2):195–202.
 47. Vargatu I. Williams textbook of endocrinology. Vol. 12, *Acta Endocrinologica (Bucharest)*. 2016. 113–113.
 48. Salonia A, Rastrelli G, Hackett G, Seminara SB, Huhtaniemi IT, Rey RA, et al. Paediatric and adult-onset male hypogonadism. *Nat Rev Dis Prim*. 2019;5(1):1–21.
 49. Al Hayek AA, Robert AA, Alshammari G, Hakami H, Al Dawish MA. Assessment of hypogonadism in men with type 2 diabetes: a cross-sectional study from Saudi Arabia. *Clin Med Insights Endocrinol Diabetes*. 2017;10.
 50. Dhindsa S, Ghanim H, Batra M, Dandona P. Hypogonadotropic hypogonadism in men with diabetes. *Diabetes Care*. 2018;41(7):1516–25.
 51. Mohamed O, Freundlich RE, Dakik HK, Grober ED, Najari B, Lipshultz LI, et al. The quantitative ADAM questionnaire: A new tool in quantifying the severity of hypogonadism. *Int J Impot Res*. 2010;22(1):20–4.
 52. Cohen J, Nassau DE, Patel P, Ramasamy R. Low testosterone in adolescents & young adults. *Front Endocrinol (Lausanne)*. 2020;10:1–6.
 53. Di Guardo F, Vloeberghs V, Bardhi E, Blockeel C, Verheyen G, Tournaye H, et al. Low testosterone and semen parameters in male partners of infertile couples undergoing IVF with a total sperm count greater than 5 Million. *J Clin Med*. 2020;9(12):3824.
 54. Gyawali P, Martin SA, Heilbronn LK, Vincent AD, Taylor AW, Adams RJT, et al. The role of sex hormone-binding globulin (SHBG), testosterone, and other sex steroids, on the development of type 2 diabetes in a cohort of community-dwelling middle-aged to elderly men. *Acta Diabetol*.

- 2018;55(8):861–72.
55. Livingston M, Kalansooriya A, Hartland AJ, Ramachandran S, Heald A. Serum testosterone levels in male hypogonadism: Why and when to check—A review. *Int J Clin Pract.* 2017;71(11):1–9.
 56. Swee DS, Gan EH. Late-onset hypogonadism as primary testicular failure. *front endocrinol (Lausanne).* 2019;10:1–5.
 57. Hackett G, Kirby M, Edwards D, Jones TH, Wylie K, Ossei-Gerning N, et al. British society for sexual medicine guidelines on adult testosterone deficiency, With Statements for UK Practice. *J Sex Med.* 2017;14(12):1504–23.
 58. Ventimiglia E, Ippolito S, Capogrosso P, Pederzoli F, Cazzaniga W, Boeri L, et al. Primary, secondary and compensated hypogonadism: a novel risk stratification for infertile men. *Andrology.* 2017;5(3):505–10.
 59. Moctezuma-Velázquez C, Low G, Mourtzakis M, Ma M, Burak KW, Tandon P, et al. Association between low testosterone levels and sarcopenia in cirrhosis: A cross-sectional study. *Ann Hepatol.* 2018;17(4):615–23.
 60. Wong N, Levy M, Stephenson I. Hypogonadism in the HIV-infected man. *Curr Treat Options Infect Dis.* 2017;9(1):104–16.
 61. Hu TY, Chen YC, Lin P, Shih CK, Bai CH, Yuan KC, et al. Testosterone-associated dietary pattern predicts low testosterone levels and hypogonadism. *Nutrients.* 2018;10(11):1–16.
 62. Gateva A, Assyov Y, Tsakova A, Kamenov Z. Classical (adiponectin, leptin, resistin) and new (chemerin, vaspin, omentin) adipocytokines in patients with prediabetes. *Horm Mol Biol Clin Investig.* 2018;34(1):1–9.
 63. Mohammed AG, Mansour AA, Ahmed JH. Effect of exogenous glucocorticoids on male hypogonadism. *Biomed Reports.* 2020;13(3):1–8.
 64. Islam Z, Akter S, Inoue Y, Hu H, Kuwahara K, Nakagawa T, et al. Prediabetes, diabetes, and the risk of all-cause and cause-specific mortality in a Japanese working population: Japan epidemiology collaboration on occupational health study. *Diabetes Care.* 2021;44(3):757–64.
 65. Campbell JA, Walker RJ, Dawson AZ, Egede LE. Prevalence of diabetes, prediabetes, and obesity in the indigenous Kuna population of Panama. *BMC*

- Public Health. 2019 Dec 28;19(1):843.
66. Lyssenko V, Laakso M. Genetic screening for the risk of type 2 diabetes: Worthless or valuable? *Diabetes Care*. 2013;36(SUPPL.2).
 67. Huemer MT, Huth C, Schederecker F, Klug SJ, Meisinger C, Koenig W, et al. Association of endothelial dysfunction with incident prediabetes, type 2 diabetes and related traits: The KORA F4/FF4 study. *BMJ Open Diabetes Res Care*. 2020;8(1):1–10.
 68. Van Herpt TTW, Ligthart S, Leening MJG, Van Hoek M, Lieveise AG, Ikram MA, et al. Lifetime risk to progress from pre-diabetes to type 2 diabetes among women and men: Comparison between American Diabetes Association and World Health Organization diagnostic criteria. *BMJ Open Diabetes Res Care*. 2020;8(2):1–9.
 69. Aldossari KK, Aldiab A, Al-zahrani JM, Al-ghamdi SH, Abdelrazik M, Batais MA, et al. Prevalence of prediabetes, diabetes, and its associated risk factors among males in Saudi Arabia: A population-based survey. 2018;2018.
 70. Andes LJ, Cheng YJ, Rolka DB, Gregg EW, Imperatore G. Prevalence of prediabetes among adolescents and young adults in the United States, 2005-2016. *JAMA Pediatr*. 2020;174(2).
 71. Mainous AG, Tanner RJ, Baker R, Zayas CE, Harle CA. Prevalence of prediabetes in England from 2003 to 2011: Population-based, cross-sectional study. *BMJ Open*. 2014;4(6):4–11.
 72. Rajput R, Rajput M, Mishra S, Ahlawat P. Prevalence of metabolic syndrome in prediabetes. *Metab Syndr Relat Disord*. 2019;17(8):406–10.
 73. Kurniawan LB, Adnan E, Mulyono B. Insulin resistance and testosterone level in Indonesian young adult males. *Rom J Intern Med*. 2020;58(2):93–8.
 74. Mohamed SF, Mwangi M, Mutua MK, Kibachio J, Hussein A, Ndegwa Z, et al. Prevalence and factors associated with pre- diabetes and diabetes mellitus in Kenya : results from a national survey. 2018;18(Suppl 3).
 75. Yu X, Duan F, Lin D, Li H, Zhang J, Wang Q, et al. Prevalence of diabetes, prediabetes, and associated factors in an adult Chinese population: Baseline of a prediabetes cohort study. *Int J Endocrinol*. 2020;2020.

76. Chakarova N, Dimova R, Grozeva G, Tankova T. Assessment of glucose variability in subjects with prediabetes. *Diabetes Res Clin Pract.* 2019;151:56–64.
77. Barbu E, Popescu MR, Popescu AC, Balanescu SM. Phenotyping the prediabetic population—a closer look at intermediate glucose status and cardiovascular disease. *Int J Mol Sci.* 2021;22(13).
78. Heianza Y, Hara S, Arase Y, Saito K, Fujiwara K, Tsuji H, et al. HbA1c 5·7-6·4 and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): A longitudinal cohort study. *Lancet.* 2011;378(9786):147–55.
79. Cohen RM, Lindsell CJ. When the blood glucose and the HbA1c don't match: Turning uncertainty into opportunity. *Diabetes Care.* 2012;35(12):2421–3.
80. Sinha N, Maiti A, Sinha A, Basu AK, Das TC. Study of serum testosterone level in males with prediabetes, before and after 3 months of metformin therapy, in patients attending a tertiary care hospital in West Bengal, Eastern India. *JMSCR.* 2019;7(1)32-43.
81. Gupta AK, Menon A, Brashear M, Johnson WD. Prediabetes: prevalence, pathogenesis, and recognition of enhanced risk. Second Edition. *Nutritional and therapeutic interventions for diabetes and metabolic syndrome.* Elsevier Inc.; 2012. 57–75 .
82. Markus MRP, Ittermann T, Baumeister SE, Huth C, Thorand B, Herder C, et al. Prediabetes is associated with microalbuminuria, reduced kidney function and chronic kidney disease in the general population: The KORA (Cooperative Health Research in the Augsburg Region) F4-Study. *Nutr Metab Cardiovasc Dis.* 2018;28(3):234–42.
83. Horáková D, Štěpánek L, Janout V, Janoutová J, Pastucha D, Kollárová H, et al. Optimal homeostasis model assessment of insulin resistance (HOMA-IR) cut-offs: A cross-sectional study in the Czech population. *Med.* 2019;55(5).
84. Ho CH, Yu HJ, Wang CY, Jaw FS, Hsieh JT, Liao WC, et al. Prediabetes is associated with an increased risk of testosterone deficiency, independent of

- obesity and metabolic syndrome. *PLoS One*. 2013;8(9):1–9.
85. Rajput R, Banerjee S. Prevalence of adult-onset hypogonadism and erectile dysfunction in males with prediabetes. *Int J Diabetes Metab*. 2018;2–7.
86. Chen L, Xie Y-M, Pei J-H, Kuang J, Chen H-M, Chen Z, et al. Sugar-sweetened beverage intake and serum testosterone levels in adult males 20-39 years old in the United States. *Reprod Biol Endocrinol*. 2018;16(1):1–7.
87. Lee DM, O’neill TW, Pye SR, Silman AJ, Finn JD, Pendleton N, et al. The european male ageing study (EMAS): Design, methods and recruitment. *Int J Androl*. 2009;32(1):11–24.
88. Sedliak M, Kralik M, Cvecka J, Buzgo G, Putala M, Ukropcova B, et al. Relation between testosterone levels and body composition, physical functioning and selected biochemical parameters in adult males. *Vnitr lek*. 2020;66(2):e37–42.
89. Valsaraj R, Sengupta N, Baidya A, Goswami S, Sahana PK. Relationship between testosterone, insulin resistance, inflammatory markers and obesity parameters in overweight and obese adolescents and adult males - a cross-sectional study. *J Evid Based Med Healthc*. 2021;8(13):823–9.

